Evidence map›Paper›PMID 21316358›Full record

ArticleEuropean journal of pharmacology2011

Tumor necrosis factor-α induces increased lung vascular permeability: a role for GSK3α/β.

Amy Barton-Pai, Carlos Feleder, Arnold Johnson

Abstract read
In one paragraph

Article in European journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Protective Effects of Luteolin onAntibiotics (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Amy Barton-PaiPharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, United States. arnie.johnson@acphs.edu
Carlos Feleder
Arnold Johnson
Albany College of Pharmacy and Health Sciences · US

Funding

NO &AP-1 MODULATE TNF-ACTIVATED LUNG ENDOTHELIAL PROTEIR01HL059901 · NHLBI · ALBANY RESEARCH INSTITUTE, INC. · PI MOUSA, SHAKER A · 1999 to 2013
$3.1M
NHLBI NIH HHS R01 HL059901NHLBI NIH HHS R01-HL-59901
6 · The paper itself

Abstract

We tested the hypothesis that glycogen synthase kinase 3α/β (GSK3α/β) modulates tumor necrosis factor-a (TNF) induced increased lung vascular permeability. Rats were treated with TNF (i.v., ~100ng/ml) or vehicle 0.5h, 4.0h and 24.0h prior to lung isolation. Rats were co-treated with the GSK3α/β inhibitors SB216763 (0.6mg/kg) or TDZD-8 (1.0mg/kg). After TNF, the isolated lung was assessed for hemodynamics, wet-dry/dry weight (W-D/D) and extravascular albumin. Extravascular albumin significantly increased at TNF-24h compared to Control. In the GSK3α/β-inhibited+TNF groups, extravascular albumin was similar to the Control and respective SB216763 and TDZD-8 groups. In separate studies, to assess GSK3α/β-activity, lung lysate was assessed for phospho-GSK3α/β-Ser(21/9), total GSK3α/β, un-phospho-β-catenin-Ser(33/37) and total β-catenin. In the TNF-4.0h group, there was no change in GSK3α/phospho-GSK3α-Ser(21) but there was an increase in GSK3β/GSK3β-Ser(9) compared to Control, indicating GSK3β activation at TNF-4.0h. GSK3β activation was verified because there was a decrease in un-phospho-β-catenin-Ser(33/37)/β-catenin in the TNF-4.0 group, a specific outcome for GSK3β activation. In the SB216763+TNF group, un-phospho-β-catenin-Ser(33/37) was similar to Control, indicating prevention of TNF-induced GSK3β activation. In the TNF-24h group, there were increases in the biomarkers of inflammation phospho-eNOS-Ser (1117) and oxidized protein, which did not occur in the SB216763+TNF-24h and TDZD-8+TNF-24h groups. In the SB216763+TNF-24h and TDZD-8+TNF-24h groups, un-phospho-β-catenin-Ser(33/37) was greater than in the Control, indicating continued inhibition of GSK3β. The data indicates that pharmacologic inhibition of GSK3β inhibits TNF induced increased endothelial permeability associated with lung inflammation.

Indexed as

Animalsbeta CateninBiomarkersCapillary PermeabilityEnzyme ActivationGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansIndolesLungMaleMaleimidesNitric Oxide Synthase Type IIIOxidation-ReductionPhosphoproteinsPhosphorylation4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dionebeta CateninBiomarkersGlycogen Synthase Kinase 3glycogen synthase kinase 3 alphaGlycogen Synthase Kinase 3 betaGSK3B protein, humanGsk3b protein, ratIndolesMaleimidesNitric Oxide Synthase Type IIIPhosphoproteinsProtein Kinase InhibitorsSB 216763SerineThiadiazolesTumor Necrosis Factor-alphaTyrosine

Identifiers

PMID21316358
PMCPMC3063390
OpenAlexW1966403189

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.